key: cord-0944786-hcwfux5w
authors: Di Noia, Vincenzo; Renna, Davide; Barberi, Vittoria; Dicivita, Mattia; Riva, Federica; Costantini, Giulia; Aquila, Emanuela Dell’; Russillo, Michelangelo; Bracco, Domenico; La Malfa, Antonia Marina; Giannarelli, Diana; Cognetti, Francesco
title: The first report on Covid-19 vaccine refusal by cancer patients in Italy: early data from a single-institute survey
date: 2021-05-26
journal: Eur J Cancer
DOI: 10.1016/j.ejca.2021.05.006
sha: 58bd35f5c079bc2bf8358db1135dee9defc62e95
doc_id: 944786
cord_uid: hcwfux5w

INTRODUCTION: Cancer-patients (pts) have an increased risk of complications from COVID-19 infection, including death, and thus they were considered as high priority subjects for COVID-19 vaccination. We report on the compliance with the COVID-19 vaccine of pts affected by solid tumors. MATERIAL AND METHODS: Cancer pts afferent to Medical Oncology-1-Unit of Regina Elena National-Cancer-Institute in Rome were considered eligible for vaccination if they were receiving systemic immunosuppressive antitumor treatment, or received it in the last 6 months, or having an uncontrolled advanced disease. The Pfizer-BNT162b2 vaccine was proposed to all candidates by phone contact or during a scheduled visit. Reasons of refusal were collected by administrating a 6-items-multiple-choice questionnaire. RESULTS: From March 1st to 20th,2021, out 914 eligible pts 102 refused vaccination (11.2%,95%CI9.1-13.2). The most frequent (>10%) reasons reported were concerns about vaccine-related adverse events (48.1%), negative interaction with concomitant antitumor therapy (26.7%) and the fear of allergic reaction (10.7%). The refusal rate (RR) after March 15th (date of AstraZeneca-AZD1222 suspension) was more than doubled compared to the RR observed before (19.7%vs8.6%,OR2.60,95%CI1.69-3.99,p<0.0001)(Fig.1B). ECOG-PS 2 was associated with higher RR compared with ECOG-PS 0-1(OR2.94,95%CI1.04-8.34,p=0.04). No statistically significant differences in RR according to other clinical characteristics were found. CONCLUSIONS: Our experience represents the first worldwide report on the adherence of cancer-pts to COVID-19 vaccination and underlines how regulatory decisions and media news-spreading could influence the success of the campaign.

Cancer patients have an increased risk of complications from COVID-19 infection, including a mortality rate of 30% if hospitalized [1] . In Italy, the Ministry of Health and FOCE confederation of oncologists/cardiologists/hematologists, work together to offer COVID-19-vaccine with high priority to frail patients affected by these diseases. The troubled authorization iter of COVID-19 vaccines, such as occurred for AstraZeneca-AZD1222, which was even suspended temporarily during March 15th -19th,2021 [2] , and the great attention reserved by media to vaccine safety information, may influence adherence to vaccination. We report on the compliance of cancer patients with COVID-19-vaccine based on a large population from a single institutional experience.

Accordingly to the government's plan, patients affected by solid tumor and afferent to Medical Oncology-1-Unit of Regina Elena National-Cancer-Institute in Rome were considered eligible for vaccination if they were receiving systemic immunosuppressive/myelosuppressive antitumor treatment, or received it in the last 6 months, or having an uncontrolled advanced disease. Pfizer-BNT162b2 vaccine with a fixed schedule was proposed to all candidates by phone contact or during a scheduled visit. After receiving adequate information from the physicians on benefits/risks ratio, patients who refused vaccination answer anonymously a 6-items-multiple-choice questionnaire (Supplementary material) to collect the specific reasons for withdrawal. The survey was conducted according to the rules of the Local Ethics Committee.

From March 1 st to 20 th ,2021 we proposed Pfizer-BNT162b2 to 914 cancer-patients. Females were 61% and the median age was 62 (range 21-97) years. Breast Cancer (31.2%), Lung Cancer (19.7%) Melanoma (14.7%) were the most frequent (>10%) tumor subtypes. The most of patients were on active treatment or received it within the last 6 months (96%) and 4% were under surveillance with progressive disease. Out of 914 eligible patients,102 refused vaccination (11.2%,95%CI9.1-13.2).The most frequent (>10%) reasons reported were concerns about vaccine-related adverse events, negative interaction with concomitant antitumor therapy and the fear of allergic reaction, recorded in 48.1%,26.7%, and 10.7 % of answers respectively (Fig.1A) .The refusal rate (RR) after March 15 th (date of AstraZeneca-AZD1222 suspension) was more than doubled compared to the RR observed before (19.7%vs8.6%,OR2.60,95%CI1.69-3.99,p<0.0001) (Fig.1B) . ECOG-PS 2 was associated with higher RR compared with ECOG-PS 0-1(OR2.94,95%CI1.04-8.34,p=0.04). No statistically significant differences in RR according to other clinical characteristics were found (Table.1) .

To our knowledge, our experience represents the first worldwide report on the withdrawal rate of COVID-19 vaccination in cancer patients. A cross-sectional survey conducted on French cancer patients before the starting of the vaccination campaign reported the unwillingness to get vaccinated in 16.6% of subjects [3] . The rate observed was higher than that reported in our study, which was otherwise based on effective withdrawals. Furthermore, in the French study more than half of the patients were under surveillance or receiving hormone therapy in contrast with our study population mostly including patients on active treatment. The overall RR of 11.2% observed in our study could be considered relevant if compared to that reported by the press for Italian health-operators (ranges from 1-3.5%), even if this estimate seems to be in contrast with the peak of 11-15% reported by some regional authorities, such as in Lombardy and Puglia [4] . Interestingly, the RR had more than doubled after the ban of AZD1222-vaccine, demonstrating how decisions by the regulatory agencies and the news-spreading by media could influence the willingness of the patient to get vaccinated. This increase of RR appears much higher than that (of 5 percentage points) reported by a pool conducted on a random sample from Italian people in the same period [5] . It is conceivable that cancer patients could be more negatively influenced by information about vaccine safety because concerns related to their frailty were more elevated. In fact, the RR was also significantly higher in patients with poorer clinical conditions (ECOG PS 2), although they represent a small subset of the study population. Our survey-study could be affected by some limitations, such as the potential risk of underestimation cannot due to untraceable patients, whose number was however limited, and the single-institutional design. However, the large sample size permits a reliable estimate of the adherence of patients even though external validation could be warranted for confirmation. Given the vulnerability of cancer patients for severe complications and mortality related to COVID-19, the dramatic drop of adherence to vaccination observed would translate into an unacceptably high cost in otherwise preventable deaths. Healthcare authorities have been called to action to overcome hesitancy on vaccination in the oncological and general population by promoting adequate education and psychological interventions [6] . To pursue a successful vaccination campaign, with the appropriate consideration for frail patients, we also suggest more clarity in the decisions by the regulatory agencies and more caution in the news-spreading of potential safety alarm, whose release too often occurred before a valid scientific revision. The drug safety and information transparency should be guaranteed to avoid the diffusion of threatening uncertainty in public opinion. 

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Agenzia Italiana del Farmaco. COVID-19 Vaccines communications

Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey

Quanti sono i medici e infermieri No Vax negli ospedali? 35 mila non risultano ancora vaccinati: cosa non torna nelle stime basse dei sindacati

italiani ora più cauti, ma il 52% è pronto a farlo subitohttps

SARS-CoV-2 vaccines for cancer patients: a call to action

*Cardiovascular comorbidities includes hearth disease, chronic obstructive pulmonary disease-asthma, diabetes, and chronic kidney disease. ** Chronic steroid use was defined as started at least 30-days before vaccine administration. ***Previous COVID-19 was defined as laboratory confirmed infection occurred before the vaccine

We thank medical oncologists, residents, nurses, hospital pharmacists and data-managers (all affiliated with Medical Oncology of Regina Elena National Cancer Institute, Rome, Italy) for their commitment to the COVID-19 vaccination campaign for cancer patients. We thank the patients afferent to our Unit and their families. 

Cancer pts have high priority for COVID-19 vaccination for their vulnerability • A refusal rate of 11.2% was found in our large cohort of eligible cancer pts